Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy

H. Mehanna; A. Kong; A. Hartley; P. Mistry; M. Dalby; T. Fulton-Lieuw; M. Robinson; A. Gray; B. Foran; M. Sen; L. O'Toole; K. Dyker; H. Al Booz; R. Moleron; S. Brennan; E. Aynsley; A. Chan; D. Srinivasan; J. Buter; J. Dunn

doi:10.1093/annonc/mdy424.046

Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy

H. Mehanna
, A. Kong
, A. Hartley
, P. Mistry
, M. Dalby
, T. Fulton-Lieuw
, M. Robinson
, A. Gray
, B. Foran
, M. Sen
, L. O'Toole
, K. Dyker
, H. Al Booz
, R. Moleron
, S. Brennan
, E. Aynsley
, A. Chan
, D. Srinivasan
, J. Buter
, J. Dunn

University of Birmingham
Queen Elizabeth Hospital
University of Warwick
Newcastle University
University of Oxford
Weston Park Hospital
St James's Institute of Oncology
Castle Hill Hospital
Bradford Institute for Health Research, BD96RJ Bradford, United Kingdom
The Bristol Haematology & Oncology Centre
NHS Grampian
Saint Luke's Radiation Oncology Network
South Tees Hospitals NHS Foundation Trust
University Hospitals Coventry and Warwickshire NHS Trust
NHS Lothian

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	viii729-viii730
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy424.046
Publication status	Published - 1 Oct 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/annonc/mdy424.046

Cite this

Mehanna, H., Kong, A., Hartley, A., Mistry, P., Dalby, M., Fulton-Lieuw, T., Robinson, M., Gray, A., Foran, B., Sen, M., O'Toole, L., Dyker, K., Al Booz, H., Moleron, R., Brennan, S., Aynsley, E., Chan, A., Srinivasan, D., Buter, J., & Dunn, J. (2018). Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii729-viii730. https://doi.org/10.1093/annonc/mdy424.046

@article{418ced3c973e4b85a312c6d62ff7577b,

title = "Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy",

author = "H. Mehanna and A. Kong and A. Hartley and P. Mistry and M. Dalby and T. Fulton-Lieuw and M. Robinson and A. Gray and B. Foran and M. Sen and L. O'Toole and K. Dyker and \{Al Booz\}, H. and R. Moleron and S. Brennan and E. Aynsley and A. Chan and D. Srinivasan and J. Buter and J. Dunn",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy424.046",

language = "English",

volume = "29",

pages = "viii729--viii730",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Mehanna, H, Kong, A, Hartley, A, Mistry, P, Dalby, M, Fulton-Lieuw, T, Robinson, M, Gray, A, Foran, B, Sen, M, O'Toole, L, Dyker, K, Al Booz, H, Moleron, R, Brennan, S, Aynsley, E, Chan, A, Srinivasan, D, Buter, J & Dunn, J 2018, 'Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii729-viii730. https://doi.org/10.1093/annonc/mdy424.046

Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy. / Mehanna, H.; Kong, A.; Hartley, A. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii729-viii730.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy

AU - Mehanna, H.

AU - Kong, A.

AU - Hartley, A.

AU - Mistry, P.

AU - Dalby, M.

AU - Fulton-Lieuw, T.

AU - Robinson, M.

AU - Gray, A.

AU - Foran, B.

AU - Sen, M.

AU - O'Toole, L.

AU - Dyker, K.

AU - Al Booz, H.

AU - Moleron, R.

AU - Brennan, S.

AU - Aynsley, E.

AU - Chan, A.

AU - Srinivasan, D.

AU - Buter, J.

AU - Dunn, J.

PY - 2018/10/1

Y1 - 2018/10/1

UR - https://www.scopus.com/pages/publications/85081529081

U2 - 10.1093/annonc/mdy424.046

DO - 10.1093/annonc/mdy424.046

M3 - Article

C2 - 32138008

SN - 0923-7534

VL - 29

SP - viii729-viii730

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy

UN SDGs

Access to Document

Other files and links

Cite this